跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAR NK-cell therapy
首页
药物
CAR NK-cell therapy
CAR NK-cell therapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
TISSUE FACTOR-TARGETING CAR-NK AND CAR-T CELL THERAPY
EP 3687555 A4
申请人: OHIO STATE INNOVATION FOUNDATION
优先权: 2017
CN
EP
US
WO
5 件公开
CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO B-CELL MATURE ANTIGEN (BCMA) AND/OR TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR (TACI)
EP 4590329 A2
申请人: ELPIS BIOPHARMACEUTICALS
优先权: 2022
CN
EP
US
WO
4 件公开
METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
EP 4752227 A3
申请人: EXUMA BIOTECH CORP
优先权: 2017
CN
EP
WO
4 件公开
PURIFYING TCR-MODIFIED T CELLS USING TCR-SPECIFIC CAR-NK CELLS
EP 4601677 A1
申请人: UNIV BERLIN CHARITE
优先权: 2022
EP
US
WO
4 件公开
CD52-DEFICIENT CELLS FOR ADOPTIVE CELL THERAPY
EP 3987008 A1
申请人: CELYAD ONCOLOGY S A
优先权: 2019
EP
US
WO
3 件公开
ANTI-IDIOTYPE ANTIBODIES AND USES THEREOF
EP 4532559 A1
申请人: MEDITERRANEA THERANOSTIC S R L
优先权: 2022
CN
EP
US
3 件公开
USE OF TRIVALENT CHROMIUM IONS AND/OR METAL CHROMIUM IN PREPARATION OF DRUG FOR IMMUNOTHERAPY OF TUMORS
US 20260240903 A1
申请人: SHENZHEN LUOHU PEOPLES HOSPITAL
优先权: 2023
CN
US
WO
3 件公开
MODIFIED NK CELL EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
EP 4487868 A1
申请人: UNIV HAMBURG EPPENDORF
优先权: 2023
EP
WO
3 件公开
Methods and compositions for transducing lymphocytes and regulating the activity thereof
US 11111505 B2
申请人: EXUMA BIOTECH CORP
优先权: 2017
US
3 件公开
METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATED EXPANSION THEREOF
EP 3430136 A2
申请人: F1 ONCOLOGY INC
优先权: 2016
EP
US
2 件公开
第 1 / 6 页
上一页
下一页
药物
反馈